Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Cidara Therapeutics Inc    CDTX

CIDARA THERAPEUTICS INC (CDTX)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/18/2018 06/19/2018 06/20/2018 06/21/2018 06/22/2018 Date
5.35(c) 5.15(c) 5.4(c) 5.2(c) 5.35(c) Last
109 633 76 479 86 994 82 018 101 435 Volume
-6.96% -3.74% +4.85% -3.70% +2.88% Change
More quotes
Financials (USD)
Sales 2018 -
EBIT 2018 -67,2 M
Net income 2018 -66,8 M
Debt 2018 -
Yield 2018 -
Sales 2019 -
EBIT 2019 -73,1 M
Net income 2019 -73,3 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 0
Capi. / Sales2019 0
Capitalization 116 M
More Financials
Company
Cidara Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of anti-infectives for the treatment of fungal infections.Its portfolio includes CD101 IV, CD101 Topical, and Cloudbreak.The company was founded by Kevin M. Forrest, Kevin... 
More about the company
Surperformance© ratings of Cidara Therapeutics Inc
Trading Rating : Investor Rating : -
More Ratings
Latest news on CIDARA THERAPEUTICS INC
06/20CIDARA THERAPEUTICS : Announces Oral Presentations on Rezafungin at Two Upcoming..
AQ
06/18CIDARA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Submissi..
AQ
06/15CIDARA THERAPEUTICS : Announces Oral Presentations on Rezafungin at Two Upcoming..
BU
05/23CIDARA THERAPEUTICS : Data to be Presented at ASM Microbe 2018 Demonstrate the E..
BU
05/22CIDARA THERAPEUTICS : Announces Offering of Common Stock and Warrants
AQ
05/22CIDARA THERAPEUTICS, INC. (NASDAQ : CDTX) Files An 8-K Entry into a Material Def..
AQ
05/22CIDARA THERAPEUTICS : offers $120 million in stock to advance anti-infective dru..
AQ
05/21CIDARA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Terminat..
AQ
05/21CIDARA THERAPEUTICS : and Rutgers University Awarded $5.5 Million Grant from NIH..
BU
05/21CIDARA THERAPEUTICS : Announces Offering of Common Stock and Warrants
AQ
More news
Sector news : Bio Therapeutic Drugs
06/20GILEAD SCIENCES : GSK takes billion-dollar drug fight with Gilead to top AIDS me..
RE
06/20Roche to Buy Rest of Cancer Firm -- WSJ
DJ
06/20Latecomer Sanofi looks to catch next wave of cancer therapies
RE
06/19Alexion Uses FDA Priority-Review Voucher for Blood Disorder
DJ
06/19Roche to Pay $2.4 Billion for Full Control of Foundation Medicine -- 2nd Upda..
DJ
More sector news : Bio Therapeutic Drugs
Latest Tweets
07:31aCidara Therapeutics $CDTX Expected to Post Earnings of -$0.59 Per Share  
12:54aGet the latest ratings for $ADRO $ETSY $BIO $VIRT $CDTX in your inbox with Ma.. 
06/16Head-To-Head Analysis: Heska $HSKA and Cidara Therapeutics $CDTX  
06/15Cidara Therapeutics Announces Oral Presentations on Rezafungin at Two Upcomin.. 
06/15Cidara Therapeutics Announces Oral Presentations on Rezafungin at Two Upcomin.. 
More tweets
Qtime:115
News from SeekingAlpha
06/08INTEGRATED BIOSCI RESEARCH ON CIDARA : What's In Store For This Promising Antibi.. 
05/31YOUR DAILY PHARMA SCOOP : Recent IPO And Offerings Review 
05/29After Hours Gainers / Losers (05/29/2018) 
05/21Cidara Therapeutics and Rutgers University awarded $5.5M grant from NIH to de.. 
05/21Cidara Therapeutics announces offering of common stock and warrants 
Chart CIDARA THERAPEUTICS INC
Duration : Period :
Cidara Therapeutics Inc Technical Analysis Chart | CDTX | US1717571079 | 4-Traders
Technical analysis trends CIDARA THERAPEUTICS INC
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Average target price 14,1 $
Spread / Average Target 170%
EPS Revisions
Managers
NameTitle
Jeffrey L. Stein President, Chief Executive Officer & Director
Scott M. Rocklage Chairman
Paul Daruwala Chief Operating Officer
Matthew W. Onaitis CFO, Secretary, CAO & General Counsel
Taylor Sandison Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
CIDARA THERAPEUTICS INC-20.59%116
GILEAD SCIENCES-0.98%92 241
VERTEX PHARMACEUTICALS3.10%39 371
REGENERON PHARMACEUTICALS-13.00%34 653
SAREPTA THERAPEUTICS INC176.22%9 432
NEUROCRINE BIOSCIENCES, INC.32.39%9 234